On the evening of April 26, Eling Pharmaceutical released its 2023 annual report. The annual report shows that against the backdrop of a high base in 2022 and demand in the respiratory medicine market returning to a normal range, the company's performance showed a correction but the overall margin was small. During the reporting period, it still achieved operating revenue of 10.318 billion yuan, firmly stabilizing the 10 billion dollar revenue mark, showing strong performance resilience. Looking at a longer time span, the revenue volume in 2023 increased significantly compared to the annual revenue of 5.825 billion yuan in 2019 before the pandemic, and the company as a whole has entered a new stage of development.
以岭药业非呼吸系统类产品营收创历史新高
Yiling Pharmaceutical's non-respiratory product revenue reached a record high
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.